Acorda Therapeutics Inc. (ACOR)

13.72
0.63 4.40
NASDAQ : Health Technology
Prev Close 14.35
Open 14.36
Day Low/High 13.51 / 14.41
52 Wk Low/High 12.55 / 36.35
Volume 538.85K
Avg Volume 948.60K
Exchange NASDAQ
Shares Outstanding 47.63M
Market Cap 685.44M
EPS 0.70
P/E Ratio 20.27
Div & Yield N.A. (N.A)

Latest News

Acorda Therapeutics Announces Management Changes

Acorda Therapeutics Announces Management Changes

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months.

Acorda To Present At Oppenheimer's 29th Annual Healthcare Conference

Acorda To Present At Oppenheimer's 29th Annual Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acorda's Chief Business Officer, will present at the Oppenheimer & Co.

Acorda Therapeutics Announces Commercial Launch Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics Announces Commercial Launch Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States.

Acorda Therapeutics To Present At Cowen Annual Health Care Conference

Acorda Therapeutics To Present At Cowen Annual Health Care Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.

Acorda Therapeutics To Present At Leerink Global Healthcare Conference

Acorda Therapeutics To Present At Leerink Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acorda's Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2018

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2018

Acorda Therapeutics, Inc. (NASDAQ: ACOR) provided financial and pipeline updates for the fourth quarter and full year ended December 31, 2018.

Acorda Appoints Peter S. Carbone Senior Vice President, Quality

Acorda Appoints Peter S. Carbone Senior Vice President, Quality

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S.

Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled For February 14, 2019

Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled For February 14, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.

First Week Of ACOR March 15th Options Trading

First Week Of ACOR March 15th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

Acorda Announces The Lancet Neurology Publication Of Phase 3 Data For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces The Lancet Neurology Publication Of Phase 3 Data For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that  The Lancet Neurology published results from SPAN℠-PD, the Phase 3 pivotal efficacy trial of INBRIJA™ (levodopa inhalation powder), also referred to as CVT-301.

Acorda Provides 2018 Highlights And 2019 Guidance At J.P. Morgan Healthcare Conference

Acorda Provides 2018 Highlights And 2019 Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37 th Annual J.

First Week Of February 15th Options Trading For Acorda Therapeutics (ACOR)

First Week Of February 15th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Acorda Therapeutics Announces FDA Approval Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics Announces FDA Approval Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

Acorda To Present At The 37th Annual J.P. Morgan Healthcare Conference

Acorda To Present At The 37th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

Noteworthy Friday Option Activity: ACOR, GPRO, AAPL

Noteworthy Friday Option Activity: ACOR, GPRO, AAPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acorda Therapeutics Inc , where a total volume of 10,115 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 141.7% of ACOR's average daily trading volume over the past month, of 713,930 shares.

"Live Well. Do Tell." (Graphic: Business Wire)

"Live Well. Do Tell." (Graphic: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art℠, a new initiative that uses the power of art to allow people with Parkinson's to help recognize and articulate their OFF period experiences.

Acorda To Present At Stifel 2018 Healthcare Conference

Acorda To Present At Stifel 2018 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.

Acorda Provides Financial And Pipeline Update For Third Quarter 2018

Acorda Provides Financial And Pipeline Update For Third Quarter 2018

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2018.

Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled For October 31, 2018

Acorda Third Quarter 2018 Update: Webcast/Conference Call Scheduled For October 31, 2018

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2018 update and financial results on Wednesday, October 31 at 8:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: IMO, RDC Downgrades: ACOR, CUZ, VBFC, VSAT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Relative Strength Alert For Acorda Therapeutics

Relative Strength Alert For Acorda Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At International Congress Of Parkinson's Disease And Movement Disorders

Acorda To Present Data For INBRIJA™ (levodopa Inhalation Powder) At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinson's Disease and Movement Disorders ® taking place October 5-9, 2018...

Acorda Announces FDA Extends INBRIJA NDA Review Period

Acorda Announces FDA Extends INBRIJA NDA Review Period

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

U.S. Court Of Appeals For The Federal Circuit Upholds District Court's Decision To Invalidate AMPYRA® (dalfampridine) Patents

U.S. Court Of Appeals For The Federal Circuit Upholds District Court's Decision To Invalidate AMPYRA® (dalfampridine) Patents

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware's decision to invalidate four AMPYRA patents.

Acorda Announces Management Transitions

Acorda Announces Management Transitions

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Rick Batycky, Ph.

Acorda Provides Financial And Pipeline Update For Second Quarter 2018

Acorda Provides Financial And Pipeline Update For Second Quarter 2018

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the quarter ended June 30, 2018.

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Second Quarter Update: Webcast/Conference Call Scheduled For August 2, 2018

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2018 update and financial results on Thursday, August 2 at 8:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, LMST, ORCL, VALE Downgrades: EXFO, NXRT, ONP Initiations: BLNK Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D+ (Sell)